Ahmed Bennis/X
Sep 28, 2025, 11:10
Mortality Reduction With SGLT2 + GLP-1 Therapy in T2D and Cardiovascular Disease
Ahmed Bennis, Professor of Cardiology at Ibn Rochd University Hospital, shared a post on X:
” SGLT2 inhibitors and GLP-1 receptor agonists. impact on mortality in diabetic patients with cardiovascular disease.
In patients with T2D and ASCVD, treatment with SGLT2-I and GLP-1RA, especially in combination, is associated with a substantial reduction in mortality.”
Read more here.
Stay updated with Hemostasis Today.
-
Sep 1, 2026, 02:41Richard Buka: Win a Trip to ASH or ISTH 2027
-
Sep 1, 2026, 02:38Christian’s Journey to Stability on Avatrombopag – ITP Support Association
-
Sep 1, 2026, 02:35Alexis Guédon: Is IL-6 Pathway Inhibition Reduce Cardiovascular Risk in Giant Cell Arteritis?
-
Aug 31, 2026, 17:11Chokri Ben Lamine: Early Recognition and Immediate Treatment of Catastrophic APS
-
Aug 31, 2026, 17:06Nikolaos Ktenopoulos: COMPASS-ARTeCAT Trial Highlights Arterial Thrombosis in Patients With Cancer
-
Aug 31, 2026, 17:01Mark Kaplan: Same LDL-C, Different Coagulation, Different Outcomes, in FH
-
Aug 31, 2026, 16:55Kemal Karaagac: Milvexian Did Not Reduce Ischemic Events but Did Not Increase Fatal Bleeding
-
Aug 31, 2026, 16:47Improving Outcomes in AF-Related Stroke Beyond Anticoagulation at ESC 2026 – ESO
-
Aug 31, 2026, 16:39Shariq Shamim: Are We Going to Start DOAC post TAVI not DAPT?